CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for cetirizine hydrochloride; pseudoephedrine hydrochloride and what is the scope of freedom to operate?

Cetirizine hydrochloride; pseudoephedrine hydrochloride is the generic ingredient in two branded drugs marketed by Aurobindo Pharma Ltd, Ivax Sub Teva Pharms, Pld Acquisitions, Ppi-dac, Sun Pharm Inds Ltd, Unichem, and Kenvue Brands, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Twenty-four suppliers are listed for this compound.

Summary for CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	7
NDAs:	7
Finished Product Suppliers / Packagers:	24
Clinical Trials:	4
DailyMed Link:	CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	N/A
Fraunhofer-Institute of Toxicology and Experimental Medicine	N/A
Sandoz	Phase 1

See all CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE clinical trials

Pharmacology for CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

Drug Class	Histamine-1 Receptor Antagonist alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Histamine H1 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

R01AA	Sympathomimetics, plain
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01AB	Sympathomimetics, combinations excl. corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01BA	Sympathomimetics
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03CA	Alpha- and beta-adrenoreceptor agonists
R03C	ADRENERGICS FOR SYSTEMIC USE
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

R06AE	Piperazine derivatives
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

S01FB	Sympathomimetics excl. antiglaucoma preparations
S01F	MYDRIATICS AND CYCLOPLEGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01GX	Other antiallergics
S01G	DECONGESTANTS AND ANTIALLERGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYRTEC-D 12 HOUR	Extended-release Tablets	cetirizine hydrochloride; pseudoephedrine hydrochloride	5 mg/120 mg	021150	1	2004-06-02

US Patents and Regulatory Information for CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Ltd	CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	090922-001	Sep 28, 2012		OTC	No	No
Aurobindo Pharma Ltd	CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212409-001	Mar 8, 2023		DISCN	No	No
Pld Acquisitions	CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	077991-001	Mar 5, 2008		OTC	No	No
Unichem	CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210507-001	Sep 10, 2024		DISCN	No	No
Ppi-dac	CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210719-001	Nov 16, 2018		OTC	No	No
Kenvue Brands	ZYRTEC-D 12 HOUR	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021150-002	Nov 9, 2007		OTC	Yes	Yes

Expired US Patents for CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kenvue Brands	ZYRTEC-D 12 HOUR	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021150-002	Nov 9, 2007
Kenvue Brands	ZYRTEC-D 12 HOUR	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021150-002	Nov 9, 2007
Kenvue Brands	ZYRTEC-D 12 HOUR	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021150-002	Nov 9, 2007
Kenvue Brands	ZYRTEC-D 12 HOUR	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021150-002	Nov 9, 2007

Market Dynamics and Financial Trajectory for Cetirizine Hydrochloride + Pseudoephedrine Hydrochloride

Last updated: April 23, 2026

What does the market landscape look like for the Cetirizine HCl + Pseudoephedrine HCl combination?

The cetirizine + pseudoephedrine hydrochloride combination sits in a dense, mature OTC and pharmacy-channel ecosystem driven by seasonal respiratory demand, generic substitution, and regulatory scrutiny of pseudoephedrine supply chains.

Demand structure

• Use case: symptomatic relief for allergic rhinitis with congestion (cetirizine antihistamine + pseudoephedrine decongestant).
• Seasonality: sales track allergy and cold/flu seasons, with revenue concentrated in peak quarters in temperate geographies.
• Channel dependence: strong OTC sales influence pricing and promotional intensity; pharmacy counter mix affects realized price for branded SKUs, while generic share influences volume.

Competitive structure

• High generic penetration: the molecules are long off-patent in major markets; this combination is typically supplied by multiple generic manufacturers.
• Branded pricing pressure: legacy branded products face sustained discounting and lower shelf pricing as generics expand.
• Supply-chain constraints on pseudoephedrine: the regulatory treatment of pseudoephedrine (and related precursor controls) tends to tighten effective supply and can shift inventory availability and wholesale pricing during tightening cycles. In the US, pseudoephedrine regulation is tied to controls on methamphetamine precursor handling under the Combat Methamphetamine Epidemic Act framework, which shapes sourcing and distribution dynamics. [1][2]

Product format mix (impacts revenue)

Revenue typically depends on:

• Tablet vs capsule vs extended formulations (where present).
• Pack size (larger packs often improve effective price per unit but can increase inventory risk).
• OTC vs behind-the-counter availability (jurisdiction-dependent).

(No specific format-level revenue split is provided in the cited sources used here; the assessment focuses on market mechanics.)

How do pseudoephedrine regulations affect commercialization and cash flow timing?

Pseudoephedrine is subject to controlled-substance precursor rules in the US and parallel controls elsewhere. These rules do not eliminate market demand, but they can change:

• Wholesale inventory cycles: procurement timing for pseudoephedrine can introduce lags and stockouts, shifting short-term sales between periods.
• Working capital: distributors and manufacturers can carry higher inventory risk if procurement windows tighten.
• Pricing volatility: when supply tightens, realized prices can lift at wholesale level, but retail pass-through varies with OTC competitive intensity.

In the US, the Combat Methamphetamine Epidemic Act established controls over listed chemicals and requires recordkeeping and retail customer verification for certain products containing pseudoephedrine. [1] The “Methamphetamine” precursor controls are further operationalized through reporting and monitoring requirements for covered entities. [2]

What are the main price-and-margin drivers for this combination?

The financial profile for cetirizine + pseudoephedrine is dominated by standard generics economics:

Core margin drivers

• Generic substitution: brand-to-generic migration compresses gross margin on branded SKUs and drives down realized price across the category.
• Promotional intensity: OTC categories are price competitive; retailers and wholesalers use trade promotions that reduce net price.
• Input supply cost: pseudoephedrine supply conditions can swing procurement costs; cetirizine pricing is typically steadier given broader generic sourcing.
• Regulatory and compliance costs: handling and reporting burden for pseudoephedrine inputs and sales compliance add overhead.

Net sales behavior

• Volume-led: unit volume often offsets pricing compression during non-disruptive seasons.
• Episode-driven: during peak allergy periods, category demand rises; during non-peak quarters, retailers carry more inventory and discount to clear.

What is the likely financial trajectory over the next 3-5 years given patent and generic realities?

For this specific combination, the market trajectory is characterized by:

Baseline expectations (structural)

• No durable brand protection (in most major markets): the combination’s value pool tends to shift toward low-cost manufacturing scale and contract sourcing.
• Ongoing category commoditization: pricing pressure increases as additional generic entrants and pack-size variants appear.
• Moderate growth driven by seasonality: top-line growth typically reflects population-level OTC consumption and population health (allergy prevalence), not product innovation.

Upside points

• Supply-tightening episodes can lift wholesale pricing temporarily, especially if pseudoephedrine procurement constraints tighten.
• Pack-size optimization and retailer-specific contracting can improve net realizations for compliant, high-throughput manufacturers.

Downside points

• Retail price compression in OTC channels during slow seasons.
• Compliance-driven discontinuation risks: products that fail to meet regulatory or supply-chain requirements can lose shelf access.

(These are market-mechanics conclusions; they do not rest on a specific company financial forecast.)

How does drug-market policy shape access and inventory behavior?

US OTC pseudoephedrine controls (operational impact)

The policy framework includes:

• Retail limits and reporting for covered products containing pseudoephedrine and ephedrine, intended to track and deter diversion. [1][2]
• Listed chemical controls for precursor availability and monitoring, affecting manufacturing and distribution compliance. [1]

Business consequence: inventory availability and restocking cadence can be influenced by retailer compliance systems and wholesale recordkeeping requirements, which affects short-term availability and thus sell-through.

What does “financial trajectory” look like by risk segment?

Below is a risk-segment view of how cash flows typically behave for generic-dominated OTC allergy congestion combinations.

Risk segment	Primary driver	Likely effect on net sales	Likely effect on margins
Seasonal demand uplift	Allergy season and cold season	Higher volumes in peak quarters	Slight margin support if retail pricing holds
Generic-driven price compression	Shelf substitution	Lower realized price per unit over time	Gross margin erosion; margin stabilized by scale and procurement
Pseudoephedrine supply constraint	Precursor controls and procurement cycles	Possible short-term channel stockouts or substitution	Higher COGS variability; possible temporary wholesale price increases
Regulatory compliance execution	Recordkeeping, retailer checks	Channel access continuity	Added compliance cost; disallowed supply events reduce revenue

What investment or R&D posture aligns with this trajectory?

With a commoditized base, the most finance-aligned postures are operational rather than discovery-led:

For manufacturers and brand owners (commercial execution)

• Scale manufacturing to lower unit cost and absorb OTC promotional intensity.
• Tight procurement and compliance programs to minimize pseudoephedrine availability disruptions and reduce compliance-related friction.
• Sustained pack and contract strategy to protect channel share and reduce net price volatility.

For R&D decision-makers (where value can still exist)

• Formulation differentiation where it is commercially accepted (e.g., improved dosing convenience) tends to have limited patent leverage, but it can defend share tactically in OTC settings.
• Supply-chain resilience investments can improve realized revenue stability without relying on IP renewal.

What are the policy citations that govern pseudoephedrine commercialization in the US?

The core legal framework referenced in US enforcement and industry compliance materials includes:

• Combat Methamphetamine Epidemic Act of 2005, which established controls affecting pseudoephedrine/ephedrine products and listed chemical handling. [1]
• Operational guidance and reporting/distribution rules for listed chemicals and covered products under the Controlled Substances Act framework and enforcement approach. [2]

Key Takeaways

1. This combination is structurally commoditized in most major markets, so the financial trajectory is driven by OTC seasonality, competitive pricing, and generic penetration rather than innovation-led growth.
2. Pseudoephedrine regulations are a material working-capital and availability variable: they can tighten supply cycles and change short-term wholesale pricing and retail sell-through timing. [1][2]
3. Net sales are volume-led and margins are scale-dependent: promotional intensity and shelf substitution typically compress realized prices; compliance and procurement discipline determine whether manufacturers can defend margin.
4. Operational resilience is the highest-leverage lever: procurement timing, compliance execution, and contract pack strategy often matter more than incremental clinical differentiation for near-term financial performance.

FAQs

1) Is this combination primarily an OTC market?

Yes. Cetirizine + pseudoephedrine hydrochloride is commonly marketed for OTC symptomatic relief for allergic rhinitis with congestion, making it sensitive to retailer pricing and seasonal promotions.

2) Why does pseudoephedrine regulation affect revenue timing?

Controls under US precursor and OTC product frameworks can influence procurement lead times, inventory availability, and retailer compliance workflows, shifting sell-through across periods. [1][2]

3) What determines pricing power in this category?

Pricing power is constrained by generic substitution and OTC promotional cycles; the main levers are channel contracting discipline, pack strategy, and scale procurement.

4) Can supply constraints create upside?

Yes. If pseudoephedrine availability tightens, wholesale pricing and inventory replenishment can change, creating short-term lift or temporary sales recovery when shelves refill.

5) Is R&D likely to change the financial trajectory materially?

Pure clinical differentiation rarely outcompetes generics in mature OTC segments. Value typically comes from tactical formulation/delivery improvements and operational execution rather than durable IP renewal.

---

References

[1] U.S. Congress. (2005). Combat Methamphetamine Epidemic Act of 2005. Public Law 109-417.
[2] Drug Enforcement Administration. (n.d.). Diversion Control Division: Methamphetamine precursor chemical controls and reporting/recordkeeping requirements (pseudoephedrine/ephedrine and listed chemicals). https://www.dea.gov/ (accessed via DEA diversion control materials)